scPharmaceuticals (NASDAQ:SCPH) Announces Quarterly Earnings Results

scPharmaceuticals (NASDAQ:SCPH) released its earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04, Zacks reports. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.

scPharmaceuticals Trading Down 0.3 %

SCPH traded down $0.01 during trading on Wednesday, hitting $3.04. 391,379 shares of the company’s stock were exchanged, compared to its average volume of 320,836. The stock has a 50 day moving average price of $3.30 and a 200 day moving average price of $3.81. scPharmaceuticals has a 1 year low of $2.75 and a 1 year high of $5.70. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The firm has a market cap of $152.12 million, a P/E ratio of -1.60 and a beta of 0.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Monday, March 3rd.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.